Seqens, a French manufacturer of active ingredients and pharmaceutical intermediates, is ramping up its R&D and manufacturing activities in India.
“We have been in India for only four years now, but it’s a growing business and the opportunity is tremendous,” said Mr. Pierre Luzeau, President & CEO of the company in an exclusive interaction with this magazine at the CPHI Barcelona.
As an integrated manufacturer and supplier across the entire value chain, Seqens offers a broad portfolio of active ingredients, pharmaceutical intermediates, and speciality chemicals including personal care ingredients. In its pharma business, the company has a portfolio of around 200 APIs while it develops new molecular entities through its CDMO activities. The company has a turnover of around Euro 1.4-bn, with the pharma related business contributing over two-third of the revenues.
“India is an important platform for us in terms of production as well development. We have production of intermediates and APIs there. And we also have R&D which we want to grow, especially for the generics business,” said Mr. Luzeau.
Mr. Christophe Eychenne-Baron, the company’s R&D Director, informed that the Seqens R&D centre in Pune is equipped with highly qualified personnel and skillsets to develop new generic APIs and development & validation of analytical methods.
“We will invest more in R&D with additional PhDs, engineers and technicians being hired in the coming months and we have also new production capacity being built at our site in Hyderabad,” said Mr. Luzeau.
The Seqens chief pointed out that the India plans are part of the “regionalisation” trend. “We believe that our customers are keen to consume materials that are sourced locally and it also allows them to derisk supply chains. Sequens is present in many countries with strong presence in China and India, and we will continue to develop our businesses there even as we continue to progressively grow our European business,” he said.
CPHI highlights
At the CPHI Barcelona, the company highlighted its entry into the cell and gene therapy area through a recent acquisition in France of a brand from Novartis. The acquired CELLforCURE’s cell and gene therapy development and production site at Les Ulis (France) will be used as a CDMO site, said Mr. Luzeau.
The company also put the spotlight on its integrated offering called ‘SeqensUP’ by which the company seeks to empower the APIs of its customers. “Through the SeqensUP, we look at improving the bioavailability of the API. This also includes all the equipment and technologies to fine tune the API, alone or with lipids polymers, to optimise the activity of the API in the body,” explained Mr. Eychenne-Baron.
Speaking about industry trends that would drive the company’s future growth, Mr. Luzeau said, “We strongly believe that the combination of chemistry, physics and biology can help find solutions for our customers problems. We want to be a provider of scientific solution to our customers. We are also focussed on the macro trend of sustainability. The capacity of a company to propose products or processes to its customer that allow to reduce the environmental footprint is very critical in our industry. We believe Seqens is very well placed with a programme that we have set up almost 15 years ago”.


1 December, 2023 13:58:19 IST 

















